← Back to Search
Obesity Is Associated With A More Severe Overactive Bladder Disease State That Is Effectively Treated With Once‐daily Administration Of Trospium Chloride Extended Release
M. Chancellor, M. Oefelein, S. Vasavada
Published 2010 · Medicine
Download PDFAnalyze on Scholarcy
Obesity is an established risk factor for urinary incontinence, yet no information exists as to the efficacy of antimuscarinic agents in this population. The goal of this study is to examine the efficacy of once daily trospium chloride (Sanctura™) XR in overweight and obese patients with the overactive bladder syndrome.
This paper references
Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study
Y. S. Hannestad (2003)
EXPRESSION OF GHRELIN RECEPTOR IN BLADDER POINTS TO A NEW LINK BETWEEN OBESITY AND THE OVERACTIVE BLADDER
P. Tyagi (2009)
Clinical Pharmacokinetics of Trospium Chloride
O. Doroshyenko (2005)
The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men.
H. Dallosso (2004)
Intravesical instillation of trospium chloride, oxybutynin and verapamil to relax the detrussor muscle of the urinary bladder: A placebo controlled, randomized clinical trial
G Frohlich (1998)
Prevalence and burden of overactive bladder in the United States
W. Stewart (2002)
Postmenopausal Hormones and Incontinence: The Heart and Estrogen/Progestin Replacement Study
D. Grady (2001)
Risk Factors for Lower Urinary Tract Symptoms in Women 40 to 60 Years of Age
Lars Alling Møller (2000)
A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women
S. Hunskaar (2008)
Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal study
W. Auwad (2008)
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
R. Dmochowski (2008)
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.
A. Nixon (2005)
[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test].
G. Fröhlich (1998)
Urinary Stress Incontinence Among Obese Women: Review of Pathophysiology Therapy
J. Cummings (2000)
Results of obesity treatment.
A. Scheen (2002)
The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women
H. Dallosso (2003)
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
D. Staskin (2007)
Urinary Incontinence in Older Women: Who Is at Risk?
J. Brown (1996)
Weight Loss to Treat Urinary Incontinence in Overweight and Obese Women
J. S. Dungan (2009)
Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial
H. Richter (2008)
This paper is referenced by
A healthy bladder: a consensus statement
E. Lukacz (2011)
Relationship between Body Mass Index and Overactive Bladder in Women and Correlations with Urodynamic Evaluation
T. Al-Shaiji (2012)
Re: Pharmacodynamics of overactive bladder drugs: shifting the curve.
Alan J. Wein (2012)
OAB Update: Focus on Trospium
Alex Gomelsky (2011)
The effects of obesity on the pelvic floor
Preeti Jain Md Mrcog (2011)
Incontinence urinaire d'effort : les femmes à risque
Sophie Conquy (2010)
Current Pharmacologic Treatment of Lower Urinary Tract Symptoms
K. Andersson (2014)
Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women
T. Shamliyan (2012)
Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians.
A. Qaseem (2014)
Modeling Acute Changes in Bladder Wall Tension, Shape and Compliance During Filling
Firdaweke G Habteyes (2014)
Obesity and pelvic floor dysfunction.
K. Ramalingam (2015)
Obesity and urinary incontinence in women: is the black box becoming grayer?
Wael Agur (2010)
Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
L. Cardozo (2016)
Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes.
R. Liu (2011)
Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?
S. Herschorn (2014)
Best Practice & Research Clinical Obstetrics and Gynaecology
Kalaivani Ramalingam (2015)
Urinary nerve growth factor in women with overactive bladder syndrome
H. Liu (2011)
Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults
M. Oefelein (2013)
Review of Lifestyle and CAM for Miscellaneous Urologic Topics (OAB and/or Incontinence, Pediatric Urology, Peyronie’s Disease, Premature Ejaculation, UTIs, Miscellaneous): Part Two
Mark A. Moyad (2014)
The impact of different intensities of exercise on body weight reduction and overactive bladder symptoms- randomised trial.
Magdaléna Hagovska (2019)
The effects of obesity on the pelvic floor
P. Jain (2011)
Effect of weight loss on urinary incontinence in women
E. Whitcomb (2011)
Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder
Edward P. Armstrong (2012)
Pharmacodynamics of Overactive Bladder Drugs: Shifting the Curve
D. Staskin (2011)
State-of-the-art office evaluation and treatment options for symptoms of an overactive bladder
John J. Kowalczyk (2012)
Treatment of Overactive Bladder Refractory to Medications
Rajveer S. Purohit (2014)
Effect of Long-term Exercise on Voiding Functions in Obese Elderly Women
I. G. Ko (2013)